Ameriprise Financial Inc Atara Biotherapeutics, Inc. Transaction History

Ameriprise Financial Inc

$358 Billion
Q1 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.41 - $2.31 $709,087 - $1.16 Million	502,899 Added 43.78%	1,651,533 $2.44 Million
Q2 2023 Aug 14, 2023	SELL	$1.5 - $3.04 $496,846 - $1.01 Million	-331,231 Reduced 22.38%	1,148,634 $1.85 Million
Q1 2023 May 15, 2023	BUY	$2.8 - $5.46 $410,046 - $799,589	146,445 Added 10.98%	1,479,865 $4.29 Million
Q4 2022 Feb 14, 2023	BUY	$2.85 - $5.18 $1.31 Million - $2.39 Million	460,844 Added 52.81%	1,333,420 $4.37 Million
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $592,768 - $1.82 Million	-207,989 Reduced 19.25%	872,576 $3.3 Million

Q2 2022 Aug 15, 2022	SELL	$4.69 - $9.84 $1.29 Million - $2.71 Million	-275,886 Reduced 20.34%	1,080,565 $8.42 Million
Q1 2022 May 16, 2022	BUY	$8.44 - $16.89 $1.52 Million - $3.04 Million	180,187 Added 15.32%	1,356,451 $12.6 Million
Q4 2021 Feb 14, 2022	BUY	$14.7 - $19.89 $6.24 Million - $8.44 Million	424,291 Added 56.42%	1,176,264 $18.5 Million
Q3 2021 Nov 15, 2021	BUY	$11.99 - $17.9 $124,492 - $185,855	10,383 Added 1.4%	751,973 $13.5 Million
Q2 2021 Aug 16, 2021	BUY	$12.89 - $16.58 $2.93 Million - $3.77 Million	227,196 Added 44.17%	741,590 $11.5 Million
Q1 2021 May 17, 2021	BUY	$14.0 - $20.72 $2.67 Million - $3.95 Million	190,669 Added 58.9%	514,394 $7.39 Million
Q4 2020 Feb 12, 2021	SELL	$12.67 - $26.23 $706,529 - $1.46 Million	-55,764 Reduced 14.69%	323,725 $6.36 Million
Q3 2020 Nov 16, 2020	SELL	$11.92 - $15.87 $214,750 - $285,913	-18,016 Reduced 4.53%	379,489 $4.92 Million
Q2 2020 Aug 14, 2020	SELL	$7.53 - $14.93 $255,741 - $507,067	-33,963 Reduced 7.87%	397,505 $5.79 Million
Q1 2020 May 15, 2020	BUY	$5.69 - $17.78 $570,320 - $1.78 Million	100,232 Added 30.26%	431,468 $3.67 Million
Q4 2019 Feb 14, 2020	BUY	$10.89 - $16.79 $48,079 - $74,127	4,415 Added 1.35%	331,236 $5.45 Million
Q3 2019 Nov 14, 2019	BUY	$12.03 - $19.94 $822,286 - $1.36 Million	68,353 Added 26.45%	326,821 $4.62 Million
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $65,246 - $140,562	3,425 Added 1.34%	258,468 $5.2 Million
Q1 2019 May 15, 2019	BUY	$28.4 - $41.74 $3.53 Million - $5.19 Million	124,354 Added 95.15%	255,043 $10.1 Million
Q4 2018 Feb 14, 2019	SELL	$30.9 - $42.97 $1.47 Million - $2.04 Million	-47,470 Reduced 26.64%	130,689 $4.54 Million
Q3 2018 Nov 14, 2018	SELL	$35.05 - $43.5 $4.48 Million - $5.56 Million	-127,769 Reduced 41.76%	178,159 $7.37 Million
Q2 2018 Aug 14, 2018	SELL	$35.15 - $51.45 $4.16 Million - $6.09 Million	-118,421 Reduced 27.91%	305,928 $11.2 Million
Q1 2018 May 15, 2018	BUY	$18.0 - $48.35 $7.64 Million - $20.5 Million	424,349 New	424,349 $16.5 Million

Others Institutions Holding ATRA

# of Institutions

Shares Held

85M

Call Options Held

18.4K

Put Options Held

51.3K

Eco R1 Capital, LLC San Francisco, CA

10.2M
Shares

$78.4 Million
0.2% of portfolio
Redmile Group, LLC San Francisco, CA

9.26M
Shares

$71.4 Million
0.25% of portfolio
Black Rock Inc. New York, NY

6.83M
Shares

$52.7 Million
0.0% of portfolio
Bank Of America Corp Charlotte, NC

6.58M
Shares

$50.7 Million
0.0% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

6.51M
Shares

$50.2 Million
0.0% of portfolio

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ameriprise Financial Inc with notifications on news.

Account